1. Home
  2. PRAX vs SOLS Comparison

PRAX vs SOLS Comparison

Compare PRAX & SOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$254.33

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Logo Solstice Advanced Materials Inc.

SOLS

Solstice Advanced Materials Inc.

HOLD

Current Price

$59.87

Market Cap

9.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
SOLS
Founded
2015
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Aerospace
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
9.2B
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
PRAX
SOLS
Price
$254.33
$59.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
21
10
Target Price
★ $650.00
$78.60
AVG Volume (30 Days)
481.4K
★ 2.0M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
★ 0.50%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 1.28
Revenue
N/A
★ $3,886,000,000.00
Revenue This Year
N/A
$7.28
Revenue Next Year
$39,256.17
$5.75
P/E Ratio
★ N/A
$46.89
Revenue Growth
N/A
★ 3.08
52 Week Low
$154.46
$40.43
52 Week High
$392.70
$90.80

Technical Indicators

Market Signals
Indicator
PRAX
SOLS
Relative Strength Index (RSI) 38.28 48.75
Support Level $237.78 $55.53
Resistance Level $356.02 $64.15
Average True Range (ATR) 12.32 2.36
MACD 2.23 0.15
Stochastic Oscillator 32.24 31.85

Price Performance

Historical Comparison
PRAX
SOLS

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About SOLS Solstice Advanced Materials Inc.

Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.

Share on Social Networks: